Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The protein p53 protects the organism against carcinogenic events by the induction of cell cycle arrest and DNA repair program upon DNA damage. Virtually all cancers inactivate p53 either by mutations/deletions of the TP53 gene or by boosting negative regulation of p53 activity. The overexpression of MDM2 protein is one of the most common mechanisms utilized by p53wt cancers to keep p53 inactive. Inhibition of MDM2 action by its antagonists has proved its anticancer potential in vitro and is now tested in clinical trials. However, the prolonged treatment of p53wt cells with MDM2 antagonists leads to the development of secondary resistance, as shown first for Nutlin-3a, and later for three other small molecules. In the present study, we show that secondary resistance occurs also after treatment of p53wt cells with idasanutlin (RG7388, RO5503781), which is the only MDM2 antagonist that has passed phase II and entered phase III clinical trials, so far. Idasanutlin strongly activates p53, as evidenced by the induction of p21 expression and potent cell cycle arrest in all the three cell lines tested, i.e., MCF-7, U-2 OS, and SJSA-1. Notably, apoptosis was induced only in SJSA-1 cells, while MCF-7 and U-2 OS cells were able to restore the proliferation upon the removal of idasanutlin. Moreover, idasanutlin-treated U-2 OS cells could be cultured for long time periods in the presence of the drug. This prolonged treatment led to the generation of p53-mutated resistant cell populations. This resistance was generated de novo, as evidenced by the utilization of monoclonal U-2 OS subpopulations. Thus, although idasanutlin presents much improved activities compared to its precursor, it displays the similar weaknesses, which are limited elimination of cancer cells and the generation of p53-mutated drug-resistant subpopulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ClinVar: improving access to variant interpretations and supporting evidence
Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1153 · Cited by 4,196
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 1×
“MDM2 has the ability to inhibit p53 functions by (i) masking its transactivation domain; (ii) targeting p53 to nuclear export; and (iii) direct ubiquitination of p53 and targeting the protein to proteasomal degradation [6].”
BackgroundSmall-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 2×
“Additionally, the limited off-target action of second generation inhibitors, such as idasanutlin or AMG232, was confirmed by comparing their cytostatic effect in cells expressing wild-type p53 versus cells deprived of p53 expression [9,11].”
BackgroundBrady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 403
Two-phase dynamics of p53 in the DNA damage response
Zhang, X.-P., Liu, F., & Wang, W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100600108 · Cited by 333 · cited 2×
“Activated p53 is able to induce apoptosis under specific circumstances [2].”
BackgroundWang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · cited 1×
“Those include Nutlin-3a and its second-generation successors, RG7112 and RG7388 from Roche [8,9], AMG232 from Amgen [10,11], CGM097 and HDM201 from Novartis [12,13], SAR405838 from Sanofi [14], MK-8242 [15], DS-3032b [16], and a stapled peptide, ALRN-6924 [17].”
BackgroundSun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290 · cited 2×
“Additionally, the limited off-target action of second generation inhibitors, such as idasanutlin or AMG232, was confirmed by comparing their cytostatic effect in cells expressing wild-type p53 versus cells deprived of p53 expression [9,11].”
BackgroundTovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · cited 1×
“Those include Nutlin-3a and its second-generation successors, RG7112 and RG7388 from Roche [8,9], AMG232 from Amgen [10,11], CGM097 and HDM201 from Novartis [12,13], SAR405838 from Sanofi [14], MK-8242 [15], DS-3032b [16], and a stapled peptide, ALRN-6924 [17].”
BackgroundMDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261 · cited 2×
“Those were MDM4, BCL-xL, ∆NTRP63, and ∆NTRP73—four genes known to regulate p53, directly or indirectly [24].”
BackgroundDual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · cited 1×
“Those include Nutlin-3a and its second-generation successors, RG7112 and RG7388 from Roche [8,9], AMG232 from Amgen [10,11], CGM097 and HDM201 from Novartis [12,13], SAR405838 from Sanofi [14], MK-8242 [15], DS-3032b [16], and a stapled peptide, ALRN-6924 [17].”
BackgroundMichaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190 · cited 2×
“In the study by Michaelis and co-workers, nutlin-3 was found to select for both p53-mutated and p53wt populations of resistant UKF-NB-3 cells, indicating that the mutation of TP53 gene is not an exclusive way of gaining resistance to the drug [18].”
Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1033 · Cited by 185
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111
A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · cited 2×
“Finally, in 2015, the activity of CGM097, another MDM2 antagonist which is now in clinical trials, was tested on a panel of 113 p53wt and 243 p53mut cell lines [33].”
BackgroundMethodArnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85 · cited 1×
“Those include Nutlin-3a and its second-generation successors, RG7112 and RG7388 from Roche [8,9], AMG232 from Amgen [10,11], CGM097 and HDM201 from Novartis [12,13], SAR405838 from Sanofi [14], MK-8242 [15], DS-3032b [16], and a stapled peptide, ALRN-6924 [17].”
BackgroundFuret, P., Masuya, K., Kallen, J., Stachyra-Valat, T., Ruetz, S., Guagnano, V., Holzer, P., Mah, R., Stutz, S., Vaupel, A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.010 · Cited by 80
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64 · cited 7×
“, SAR405838 [21,22], MI-63 [23], and HDM201 [24].”
BackgroundInfluentialHoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
Self-citationLaroche, A., Chaire, V., Algeo, M.-P., Karanian, M., Fourneaux, B., & Italiano, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16345 · Cited by 38
Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26064 · Cited by 36 · cited 1×
“Those include Nutlin-3a and its second-generation successors, RG7112 and RG7388 from Roche [8,9], AMG232 from Amgen [10,11], CGM097 and HDM201 from Novartis [12,13], SAR405838 from Sanofi [14], MK-8242 [15], DS-3032b [16], and a stapled peptide, ALRN-6924 [17].”
BackgroundPhelps, D., Bondra, K., Seum, S., Chronowski, C., Leasure, J., Kurmasheva, R. T., Middleton, S., Wang, D., Mo, X., & Houghton, P. J. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25465 · Cited by 27
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“RG7388 activates p53 to inhibit hematological tumors(345) and solid tumors,(346,347) but long-term administration may lead to p53 mutations and drug resistance.(348,349)”
BackgroundDrug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Mechanism of interaction between autophagy and apoptosis in cancer
Das, S., Shukla, N., Singh, S. S., Kushwaha, S., & Shrivastava, R. (2021) · Apoptosis · doi:10.1007/s10495-021-01687-9 · Cited by 255
Therapeutics targeting p53-MDM2 interaction to induce cancer cell death
Koo, N., Sharma, A. K., & Narayan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095005 · Cited by 153
Metadata
- Authors
- Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-10-24
- Volume
- 10
- Issue
- 11
- Pages
- 396
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2898148116
- Cited by
- 73
- References
- 26
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.